These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 15750036)

  • 21. [Pharmacokinetic characteristics and antimicrobial spectrum of teicoplanin].
    Paganini H; Marin M
    Medicina (B Aires); 2002; 62 Suppl 2():52-5. PubMed ID: 12481490
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Heterologous expression of glycopeptide resistance vanHAX gene clusters from soil bacteria in Enterococcus faecalis.
    Hasman H; Aarestrup FM; Dalsgaard A; Guardabassi L
    J Antimicrob Chemother; 2006 Apr; 57(4):648-53. PubMed ID: 16476725
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Teicoplanin vs vancomycin: cost-effectiveness comparisons.
    Rybak MJ
    Hosp Formul; 1993 Jan; 28 Suppl 1():28-32. PubMed ID: 10123835
    [TBL] [Abstract][Full Text] [Related]  

  • 24. What's new on the antimicrobial horizon?
    Song JH
    Int J Antimicrob Agents; 2008 Dec; 32 Suppl 4():S207-13. PubMed ID: 19134521
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The efficacy and safety of daptomycin: first in a new class of antibiotics for Gram-positive bacteria.
    Rybak MJ
    Clin Microbiol Infect; 2006 Mar; 12 Suppl 1():24-32. PubMed ID: 16445721
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Glycopeptide antibiotics: evolving resistance, pharmacology and adverse event profile.
    Henson KE; Levine MT; Wong EA; Levine DP
    Expert Rev Anti Infect Ther; 2015; 13(10):1265-78. PubMed ID: 26165756
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Vancomycin resistance: are there better glycopeptides coming?
    Linden PK
    Expert Rev Anti Infect Ther; 2008 Dec; 6(6):917-28. PubMed ID: 19053904
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Biosynthesis, biotechnological production, and application of teicoplanin: current state and perspectives.
    Jung HM; Jeya M; Kim SY; Moon HJ; Kumar Singh R; Zhang YW; Lee JK
    Appl Microbiol Biotechnol; 2009 Sep; 84(3):417-28. PubMed ID: 19609520
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Susceptibility of methicillin-resistant Staphylococcus aureus to vancomycin, teicoplanin, linezolid, pristinamycin and other antibiotics.
    Samra Z; Ofer O; Shmuely H
    Isr Med Assoc J; 2005 Mar; 7(3):148-50. PubMed ID: 15792257
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Chemical modification of glycopeptide antibiotics].
    Pavlov AIu; Preobrazhenskaia MN
    Bioorg Khim; 1998 Sep; 24(9):644-62. PubMed ID: 9813730
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [New therapeutic strategies with teicoplanin].
    Carbone E; Nacinovich F; Stamboulian D
    Medicina (B Aires); 2002; 62 Suppl 2():25-9. PubMed ID: 12481485
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Selection of a surrogate agent (vancomycin or teicoplanin) for initial susceptibility testing of dalbavancin: results from an international antimicrobial surveillance program.
    Jones RN; Sader HS; Fritsche TR; Hogan PA; Sheehan DJ
    J Clin Microbiol; 2006 Jul; 44(7):2622-5. PubMed ID: 16825398
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Non-natural aglycones of glycopeptide antibiotics of the vancomycin group. Synthesis and antibacterial activity].
    Pavlov AIu; Olsuf'eva EN; Miroshnikova OV; Reznikova MI; Lazhko EI; Malabarba A; Ciabatti R; Preobrazhenskaia MN
    Bioorg Khim; 1997 May; 23(5):410-21. PubMed ID: 9290051
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dalbavancin, a long-acting lipoglycopeptide for the treatment of multidrug-resistant Gram-positive bacteria.
    Decousser JW; Bourgeois-Nicolaos N; Doucet-Populaire F
    Expert Rev Anti Infect Ther; 2007 Aug; 5(4):557-71. PubMed ID: 17678421
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical relevance of increasing glycopeptide MICs against Staphylococcus aureus.
    Gould IM
    Int J Antimicrob Agents; 2008 Apr; 31 Suppl 2():1-9. PubMed ID: 18485997
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Glycopeptide-induced cutaneous adverse reaction].
    Nosbaum A; Rozières A; Ben Said B; Nicolas JF; Bérard F
    Ann Dermatol Venereol; 2010 May; 137(5):341-2. PubMed ID: 20470913
    [No Abstract]   [Full Text] [Related]  

  • 37. [Glycopeptides and the newborn infant's kidney].
    Fanos V; Benini D; Vinco S; Pizzini C; Khoory BJ
    Pediatr Med Chir; 1997; 19(4):259-62. PubMed ID: 9508651
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antimicrobial activity of a novel peptide deformylase inhibitor, LBM415, tested against respiratory tract and cutaneous infection pathogens: a global surveillance report (2003-2004).
    Watters AA; Jones RN; Leeds JA; Denys G; Sader HS; Fritsche TR
    J Antimicrob Chemother; 2006 May; 57(5):914-23. PubMed ID: 16549511
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of the MicroScan system and the agar dilution assay for Quinupristin/Dalfopristin susceptibility of Enterococcus faecium.
    Kim YR; Kim SI; Hur JA; Kim YJ; Wie SH; Park YJ; Kang MW
    Ann Clin Lab Sci; 2007; 37(3):260-2. PubMed ID: 17709691
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Bacterial resistance to vancomycin and other glycopeptide antibiotics: an emerging threat].
    Kłoszewska M; Markiewicz Z
    Postepy Biochem; 1999; 45(2):122-36. PubMed ID: 10581636
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.